Various aspects of the relationship between vitiligo and the COVID‐19 pandemic or SARS‐CoV‐2 vaccines: Clinical pearls for dermatologists

Background Coronavirus disease 2019 (COVID‐19) has given rise to several new onset or exacerbated dermatologic disorders including vitiligo. Aim and Method Here, we present different aspects of relationship between SARS‐CoV‐2 infection or its associated vaccines and vitiligo and aim to provide solutions to overcome the potential challenges. Results and Conclusion In brief, as the benefits overweigh the risks and since vaccine‐triggered de novo or flares of vitiligo are uncommon and benign, these patients are recommended to get SARS‐CoV‐2 vaccines. Moreover, in individuals with previously recognized vitiligo, who are at risk of developing SARS‐CoV‐2 infection or those who are currently infected, special dermatologic consultation is needed in order to balance the immunosuppressive agents in their therapeutic regimen to prevent COVID‐related morbidity and mortality.